GNS collaborates to predict ADEs and readmissions
GNS Healthcare of Cambridge, Mass., will collaborate with David W. Bates, MD, MSc, and the Brigham and Women’s Hospital (BWH), a teaching hospital affiliated with the Harvard Medical School in Boston, to predict adverse drug events (ADEs) and hospital readmissions for patients admitted with congestive heart failure.
The collaboration will use GNS’s REFS platform and data from the electronic health records (EHRs) of patients treated by Boston-based Partners HealthCare. Researchers will identify the hidden, underlying pathways and relationships that are driving readmissions and ADEs. Once identified, these can be harnessed to reduce the adverse impact these issues have on people’s health, GNS said. Preventable adverse events are estimated to cost the U.S. healthcare system as much as $50 billion annually.
Beyond predicting which patients are at high-risk of an ADE or readmission, collaborators will aim to identify interventions that help professionals prevent these events. The collaboration complements work GNS is doing with pharmacy benefit managers related to ADE predictions, efforts with providers in predicting ‘never events’ and other analytics efforts.
“GNS Healthcare has developed supercomputer-driven, hypothesis-free technologies to extract actionable insights from large, complex healthcare datasets,” Bates, chief of the division of General Internal Medicine and Primary Care at BWH, professor of Medicine at Harvard Medical School, and a professor of Health Policy and Management at the Harvard School of Public Health, said. “The hypothesis-free approach represents an exciting way to identify non-obvious combinations of conditions, drugs and other factors that lead to adverse events, and reveal what activities can mitigate them. This has the potential to dramatically increase the quality of patient care while reducing overall costs.”
The collaboration will use GNS’s REFS platform and data from the electronic health records (EHRs) of patients treated by Boston-based Partners HealthCare. Researchers will identify the hidden, underlying pathways and relationships that are driving readmissions and ADEs. Once identified, these can be harnessed to reduce the adverse impact these issues have on people’s health, GNS said. Preventable adverse events are estimated to cost the U.S. healthcare system as much as $50 billion annually.
Beyond predicting which patients are at high-risk of an ADE or readmission, collaborators will aim to identify interventions that help professionals prevent these events. The collaboration complements work GNS is doing with pharmacy benefit managers related to ADE predictions, efforts with providers in predicting ‘never events’ and other analytics efforts.
“GNS Healthcare has developed supercomputer-driven, hypothesis-free technologies to extract actionable insights from large, complex healthcare datasets,” Bates, chief of the division of General Internal Medicine and Primary Care at BWH, professor of Medicine at Harvard Medical School, and a professor of Health Policy and Management at the Harvard School of Public Health, said. “The hypothesis-free approach represents an exciting way to identify non-obvious combinations of conditions, drugs and other factors that lead to adverse events, and reveal what activities can mitigate them. This has the potential to dramatically increase the quality of patient care while reducing overall costs.”